Somatotropin Deficiency Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Somatotropin Deficiency Treatment Market is segmented By Type (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency) By Treatment (Recombinant Human Growth Hormone, Somatotropin Injection, Others) By Route of Administration (Intravenous, Intramuscular, Others) By End-User (Hospitals, Specialty Clinics, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global Somatotropin Deficiency Treatment Market reached US$ YY billion in 2023 and is expected to reach US$ YY billion by 2031, growing with a CAGR of YY% during the forecast period 2024-2031.

Somatotropin deficiency has been prevented, and the levels of the hormone are maintained with the medications and treatment. A number of companies manufacturing intravenous and intramuscular somatotropin drugs have been in force. Alternative injections with different trade names are introduced to make them available to individuals with hormone deficiencies. 

The somatotropin injection segment accounts for over half of the market share. Similarly, North America dominates the somatotropin deficiency market due to the improved healthcare infrastructure, the number of launches by the companies, and the research and technology in the region holds the region to be dominant in market share. 

Market Scope

For more details on this report - Request for Sample

Market Dynamics

Increase in product approvals  

The increase in the number of product approvals is driving the market growth. For instance, on April 28, 2023, Novo Nordisk stated that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for children and adults. The product approvals have been increasing with the increase of individuals choosing somatotropin treatments with short postures and individuals suffering from dwarfism. Thus, the increase in product approvals is expected to drive market growth in the forecast period. 

High cost of treatment 

The high cost of the treatment procedure will decline the market’s growth. Treating growth hormone deficiency involves regular synthetic human growth hormone injections, and children receive daily injections. Treatment usually lasts several years, although results are often seen as soon as three to four months after the injections are started. For instance, according to NIH, the cost-effectiveness and cost-utility of treating children aged 5 to 16 years with somatropin was estimated at approximately $8,900. 

Additionally, GH therapy is expensive, at current prices, it may cost $ 20,000 or more per year for a 30-kg child, and because GH therapy is usually continued until the final adult height is reached, treatment can last 5 years or more. Thus, the treatment's high costs will impact the market's growth. 

Segment Analysis

The global somatotropin deficiency treatment market is segmented based on type, treatment, route of administration, end-user and region.

The somatotropin injections  from the treatment type segment accounted for approximately 42.3% of the somatotropin deficiency  market share

The somatotropin injections from the treatment type segment accounted for approximately 42.3%. Somatropin injection replaces growth hormone in adults and children with growth hormone deficiency. Somatropin injection also increases growth in children with conditions that affect average growth and development. Somatropin injection also increases growth in children with conditions that affect average growth and development. The benefit associated with the somatotropin injection over the other treatment procedures is holding the segment in the dominant position.

Somatropin injection (Serostim) increases body weight and physical endurance in patients with human immunodeficiency virus (HIV) with HIV-associated wasting syndrome. Somatotropin injection helps replace the natural hormone and provides the proper posture and development of the body.

Geographical Penetration

North America is estimated to hold about 41.4% of the total market share throughout the forecast period

North America is expected to hold a significant position in the market share. The increase in product approvals, improved healthcare, and increased research and technology hold the region in a dominant position.

For instance, on August 25, Ascendis Pharma announced that the US Food and Drug Administration has approved lonapegsomatropin-tcgd (SKYTROFA) for the treatment of pediatric patients one year and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH).

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for all the markets worldwide, including the global somatotropin deficiency market. As countries grappled with lockdowns, the diagnostic and treatment procedures were delayed and postponed. The patients with the deficiency could not reach the hospitals as the lockdown was implemented. 

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting supply chains worldwide. The key companies involved in the manufacturing of products treating the deficiency have halted. The companies have shifted the focus toward manufacturing COVID-19 drugs and vaccines.

With the outbreak of the pandemic, individuals did not prioritize somatotropin deficiency as the major risk and faced complications on the onset of severe conditions. Thus, COVID-19 impacted the market negatively. However, these measures were vital to safeguard the health of the workforce and maintain essential operations during the pandemic.

Key Developments

• On June 28, 2023, Pfizer Inc. and OPKO Health Inc. announced that the U.S. Food and Drug Administration (FDA) had approved NGENLA (somatropin-gala), a once-weekly, human growth hormone analogue indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
• On November 17, 2022, VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, released for the first time detailed clinical data from its pivotal Phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.

Competitive Landscape

The major global players in the market include Pfizer, Lilly Eli& Co., Novo Nordisk Inc., Genentech, EMD Serono, Inc., Ferring Pharmaceuticals, Shree Venkatesh Internation Limited, Omicron Pharma, Lexicare Pharma Pvt. Ltd., and AnkeBio Co., Ltd among others.

Why Purchase the Report?

• To visualize the global somatotropin deficiency market segmentation based on type, treatment, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of somatotropin deficiency market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global somatotropin deficiency market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies